| 0.0004 0 (0%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.
Sat, 19 Sep 2026
Syros Pharmaceuticals stock edges higher after recent clinical and pipeline updates - AD HOC NEWS
Thu, 24 Apr 2025
SYROS PHARMACEUTICALS (SYRS) Stock Price, News & Analysis - Stock Titan
Tue, 15 Apr 2025
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - PR Newswire
Fri, 21 Mar 2025
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Tue, 04 Mar 2025
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com
Wed, 13 Nov 2024
U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|